ArticlePakistan journal of medical sciences
Outcomes of topiramate for prophylaxis of chronic migraine headache.
Article in Pakistan journal of medical sciences. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To explore the prophylactic outcome and tolerability of topiramate in patients suffering from chronic episodes of migraine. Methods: A prospective, non-interventional study was conducted at the Neurology Department of Nishtar Medical University & Hospital Multan from 17th Aug 2020 to 17th Aug 2021. The eligible patients were administered topiramate (flexible dose) for six months while the treatment was continued for another six months upon the advice of the physician. The patients were analyzed for improvement in migraine intensity and adverse effects of the evaluated drug at 2 Results: Out of the total of one hundred enrolled patients, 30 discontinued the study due to unavoidable adverse effects, loss in the follow-up period, and other unknown reasons. The median endpoint dose was 45 mg/dl ± 20.5mg/day. Both median days with migraine episodes and median pain intensity score significantly reduced from 7 to 1.5 days and from 16 to 2.75, respectively (p<0.01). Women who were found to have menstruation-related migraines reported a decrease in the median number of migraine episodes from 3.0 to 0.8 (p=0.01). The utilization of triptan reduced significantly along with significant improvement in self-reported impairment of life. Nausea (2.5%) and paresthesia (5.7%) were the most reported adverse effects. Conclusion: Topiramate not only significantly prevents migraine intensity and frequency of episodes but is also well-tolerated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.